Two Phase 1, Open‐Label, Single‐Dose, Randomized, Crossover Studies to Assess the Pharmacokinetics, Safety, and Tolerability of Orally Administered Granules of Secnidazole (2 g) in Healthy Female Volunteers Under Different Administration Conditions

Bacterial vaginosis (BV) is the most common vaginal infection in reproductive‐age women and a significant risk factor for sexually transmitted diseases and pregnancy complications. Standard 5‐ to 7‐day antimicrobial treatments for BV are associated with high rates of recurrence and adverse events. SYM‐1219 is a novel granule formulation containing 2 g of secnidazole, developed as an oral, single‐dose BV treatment. Two phase 1, open‐label, single‐center, randomized, crossover trials (studies 102 and 103) assessed the pharmacokinetics and safety of SYM‐1219 single doses (≥7‐day washout between doses) in healthy, nonpregnant women aged 18 to 65 years inclusive. Study 102 compared SYM‐1219 in applesauce in fasted vs fed states. Study 103 compared SYM‐1219 (fasted) in pudding and yogurt vs applesauce. Studies 102 and 103 each dosed 24 subjects (mean [standard deviation] ages, 36 [1.8] and 40 [11.6] years, respectively). In both studies the 90% confidence intervals for all treatment comparisons of maximum plasma concentration, area under the concentration‐time curve from 0 to last measurable concentration and to infinity, geometric mean ratios were within 80% to 125%, demonstrating bioequivalence. In both studies median fasted time to maximum plasma concentration was 4 hours (6 hours fed in study 102), and mean half‐life ranged from 17 to 19 hours. Treatment‐emergent adverse events occurred in 70.8% and 83.3% subjects in studies 102 and 103, respectively, most commonly headache (41.7% and 50.0%) and gastrointestinal treatment‐emergent adverse events. The pharmacokinetics of SYM‐1219 were similar in fed and fasted states and when administered in different foods.